Charles River Laboratories (CRL)vsDanaher Corporation (DHR)
CRL
Charles River Laboratories
$267.49
+0.75%
HEALTHCARE · Cap: $11.30B
DHR
Danaher Corporation
$204.76
+2.39%
HEALTHCARE · Cap: $125.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 523% more annual revenue ($25.11B vs $4.03B). DHR leads profitability with a 16.0% profit margin vs -4.6%. CRL appears more attractively valued with a PEG of 0.12. DHR earns a higher WallStSmart Score of 66/100 (B-).
CRL
Hold45
out of 100
Grade: D
DHR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.3%
Fair Value
$162.24
Current Price
$267.49
$105.25 premium
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$204.76
$86.88 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Areas to Watch
1.2% revenue growth
Elevated debt levels
ROE of -6.3% — below average capital efficiency
Earnings declined 17.3%
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRL
The strongest argument for CRL centers on PEG Ratio. PEG of 0.12 suggests the stock is reasonably priced for its growth.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : CRL
The primary concerns for CRL are Revenue Growth, Debt/Equity, Return on Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
CRL profiles as a turnaround stock while DHR is a mature play — different risk/reward profiles.
CRL carries more volatility with a beta of 1.40 — expect wider price swings.
DHR is growing revenue faster at 5.5% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 45/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Charles River Laboratories
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?